By Heather Hobbs
BRINGING YOU THE LATEST NEWS & EVENTS FROM THE SCIENCE INDUSTRY
Protein Degradation Centre to Revolutionise Drug Discovery
“Dundee is right at the heart of these efforts. We are one of a handful of institutions leading the world in TPD and this Centre is integral to our ambition of establishing Dundee as the undisputed pinnacle for training and innovating in TPD research. Our new home will provide opportunities for growth and to capitalise on the expertise we have established here. It will help to accelerate innovation and will also attract further investment and major collaboration partners in the pharmaceutical industry.”
Lab facility at the CeTPD, University of Dundee
The University of Dundee is launching a new translational research centre, boosting its world-leading position in a field of chemical biology that is revolutionising drug discovery, while helping to facilitate the development of high growth companies and create skilled jobs.
The Centre for Targeted Protein Degradation (CeTPD) will be housed at the Technopole site adjacent to Dundee’s School of Life Sciences, with a fundraising target of £5 million being met by a mixture of public and private sources as well as University funds. The existing two-storey building will be fitted out with state-of-the-art facilities to allow Professor Alessio Ciulli and colleagues to expand their pioneering work in an area that has attracted billions of pounds of investment globally in the last five years.
The core team working on targeted protein degradation at the University will grow from around 25 currently to 50 when their labs are relocated to the new Centre, with further planned expansion.
Targeted protein degradation co-opts the cell’s natural disposal systems to remove disease-causing proteins and is applicable to diverse therapeutic areas including oncology, dermatology, immunology and respiratory diseases. As an entirely new approach, it provides hope of treating diseases previously thought to be undruggable. The first degrader drugs of these kind are advancing in clinical trials against cancer.
Professor Ciulli has revealed fundamental insights into the working of the degrader molecules that he designed and that are used across the globe. These and other discoveries have led to significant collaborations with some of the world’s largest pharmaceutical companies. Amphista Therapeutics, the University spin out he founded, last month received a near-£40 million investment to further its work developing new drugs for a range of diseases.
“Targeted protein degradation is one of the most exciting areas of scientific study to have emerged in many years, one which is revolutionising drug development,” said Professor Ciulli. “We are only beginning to explore the true potential of TPD to produce next- generation therapeutics for a variety of diseases.
CeTPD at the Technopole site adjacent to Dundee’s School of Life Sciences
Promoting further commercialisation is a key aim of CeTPD, which will be sited next to the new Tay Cities Regional Innovation Hub. Funded as part of the Tay Cities Deal, the hub aims to attract world-class life sciences innovation and entrepreneurial expertise to drive high-growth company formation, providing new treatments and technologies.
The CeTPD is expected to contribute to a pipeline of spinout companies translating exceptional fundamental research into products that benefit patients across the world and underpin successful commercial entities.
Work to fit out the Centre is already underway and is expected to be completed by early 2022.
More information online:
ilmt.co/PL/VqyQ 55129pr@reply-direct.com
Senior Scientist and team leader William Farnaby added: “Our new Centre for Targeted Protein Degradation at the University of Dundee will provide a state-of-the-art environment to carry out world leading research, in one of today’s most exciting and innovative areas of scientific study. This facility will allow us to build on the breakthrough science in this area that has emerged from Dundee in recent years. We will be able to push the boundaries with respect to how we discover and study targeted protein degraders, for example by enhancing how we study their cellular behaviour using advanced imaging techniques.”
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196
